Q4 2024 Earnings Call Transcript February 27, 2025 Verona Pharma plc misses on earnings expectations. Reported EPS is $-0.4 ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions ...

Sino Biopharmaceutical Limited announced on Thursday that it had signed an exclusive strategic cooperation agreement with ...

UTHR beats fourth-quarter estimates for both earnings and sales. Tyvaso sales fall short of estimates. Stock down in pre-market trading.

Treatments include acupuncture, massage, and nebulized glutathione, helping combat toxic smoke exposure. The clinics have gained popularity, treating over 1,000 responders and providing not just ...

Verona has evaluated nebulized Ohtuvayre™ in its Phase 3 clinical program ENHANCE ("Ensifentrine as a Novel inHAled Nebulized COPD thErapy") for COPD maintenance treatment. Ohtuvayre™ met the primary ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics is the firm’s top pick in Specialty Pharma in 2025 ...

Viral croup often presents similarly to an upper respiratory infection, with 12-72 h of low-grade fever and coryza. Narrowing of the larynx leads to stridor, increased respiratory rate, respiratory ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or nebulized Tyvaso, for the treatment of idiopathic ...

A case study by Wu et al. [23] reported lidocaine toxicity in a 48-kg woman with multiple health conditions receiving nebulized lidocaine before bronchoscopy. She received an approximate total ...